222 related articles for article (PubMed ID: 35718660)
1. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.
Cheeley MK; Saseen JJ; Agarwala A; Ravilla S; Ciffone N; Jacobson TA; Dixon DL; Maki KC
J Clin Lipidol; 2022; 16(4):361-375. PubMed ID: 35718660
[TBL] [Abstract][Full Text] [Related]
2. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
3. Statin Intolerance: an Overview of US and International Guidance.
Cheeley MK; Clegg K; Lockridge C; Schubert TJ; Jones LK
Curr Atheroscler Rep; 2023 Aug; 25(8):517-526. PubMed ID: 37410332
[TBL] [Abstract][Full Text] [Related]
4. The nocebo effect in the context of statin intolerance.
Tobert JA; Newman CB
J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103
[TBL] [Abstract][Full Text] [Related]
5. Statin Intolerance: the Clinician's Perspective.
Stulc T; Ceška R; Gotto AM
Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
[TBL] [Abstract][Full Text] [Related]
6. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
Krishnamurthy A; Bradley C; Ascunce R; Kim SM
Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
[TBL] [Abstract][Full Text] [Related]
7. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
8. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice.
Bosco G; Di Giacomo Barbagallo F; Spampinato S; Lanzafame L; Di Pino A; Piro S; Purrello F; Scicali R
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983444
[TBL] [Abstract][Full Text] [Related]
9. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
[TBL] [Abstract][Full Text] [Related]
11. Advances in the management of statin myopathy.
Gallo A; Perregaux J; Bruckert E
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):142-151. PubMed ID: 33278129
[TBL] [Abstract][Full Text] [Related]
12. Management of Statin Intolerance in 2018: Still More Questions Than Answers.
Toth PP; Patti AM; Giglio RV; Nikolic D; Castellino G; Rizzo M; Banach M
Am J Cardiovasc Drugs; 2018 Jun; 18(3):157-173. PubMed ID: 29318532
[TBL] [Abstract][Full Text] [Related]
13. [Practical approach to statin intolerance].
Štulc T; Beránková Š; Češka R
Vnitr Lek; 2015 Nov; 61(11):936-41. PubMed ID: 26652780
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with statin intolerance.
Martirossian AN; Goldberg AC
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101714. PubMed ID: 36345572
[TBL] [Abstract][Full Text] [Related]
15. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
16. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
17. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms.
Orringer CE; Grant JK; Tokgozoglu L
Curr Atheroscler Rep; 2022 Nov; 24(11):839-847. PubMed ID: 36001213
[TBL] [Abstract][Full Text] [Related]
18. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management.
Iatan I; Mancini GBJ; Yeoh E; Hegele RA
Expert Rev Cardiovasc Ther; 2023 Jun; 21(6):423-435. PubMed ID: 37212306
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan.
Chen WJ; Wen YC; Fox KM; Shen LJ; Lin LY; Qian Y; Zhao Z; Rane PP; Hsiao FY
J Eval Clin Pract; 2020 Aug; 26(4):1171-1180. PubMed ID: 31646715
[TBL] [Abstract][Full Text] [Related]
20. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
